iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Significant Vendor (Details Textual)

Significant Vendor (Details Textual) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
Significant Vendor (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Jun. 30, 2013	Jun. 30, 2014
Significant Vendor [Line Items]
Accounts Payable, Current	$ 984,000us-gaap_AccountsPayableCurrent		$ 984,000us-gaap_AccountsPayableCurrent			$ 297,000us-gaap_AccountsPayableCurrent
Accrued Liabilities, Current	491,000us-gaap_AccruedLiabilitiesCurrent		491,000us-gaap_AccruedLiabilitiesCurrent			98,000us-gaap_AccruedLiabilitiesCurrent
Research and Development Expense	731,000us-gaap_ResearchAndDevelopmentExpense	585,000us-gaap_ResearchAndDevelopmentExpense	1,916,000us-gaap_ResearchAndDevelopmentExpense	1,137,000us-gaap_ResearchAndDevelopmentExpense
General and Administrative Expense Settlement	1,302,000us-gaap_GeneralAndAdministrativeExpense	1,051,000us-gaap_GeneralAndAdministrativeExpense	2,352,000us-gaap_GeneralAndAdministrativeExpense	1,999,000us-gaap_GeneralAndAdministrativeExpense
Accounts Receivable, Net, Current, Total	584,000us-gaap_AccountsReceivableNetCurrent		584,000us-gaap_AccountsReceivableNetCurrent			205,000us-gaap_AccountsReceivableNetCurrent
Revenue, Net, Total	367,000us-gaap_SalesRevenueNet	0us-gaap_SalesRevenueNet	1,186,000us-gaap_SalesRevenueNet	0us-gaap_SalesRevenueNet
Settlement Agreement [Member]
Significant Vendor [Line Items]
Accounts Payable, Current					1,200,000
Accrued Liabilities, Current					1,700,000
Research and Development Expense			1,040,000
Prepaid Expense					1,000,000
General and Administrative Expense Settlement			700,000
Earnings From Reversal of Expenses			1,900,000
Interest Expense, Total			122,000
Amended Agreement [Member]
Significant Vendor [Line Items]
Research and Development Expense					1,007,000
Accounts Receivable, Net, Current, Total					1,007,000
Revenue, Net, Total	367,000		1,186,000
Fraunhofer [Member]
Significant Vendor [Line Items]
Accounts Payable, Current	584,000		584,000			205,000
Accrued Liabilities, Current	338,000		338,000
Research and Development Expense	367,000	306,000	1,186,000	(451,000)
Royalty Expense			200,000
Royalty Guarantees, Commitments, Amount	$ 4,000,000		$ 4,000,000